For Chronic Myeloid Leukemia Patient Group Advocates

ELN Recommendations 2020: patient-friendly summary now in 12 languages!

ASH 2020 CML Advocates Network Conference Report

632 Chronic Myeloid Leukemia: Therapy— Building The Future CML.

• 45 Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212. Itaru Matsumura, MD, Ph.D.
• 46 Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Before Trial. Tim H Brümmendorf, MD.
• 47 Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. Massimiliano Bonifacio, MD.
• 48 Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML. Jorge E. Cortes, MD.
• 49 Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes. Naranie Shanmuganathan, FRACP, FRCPA, MBBS.
• 50 Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Patrizia Pregno.

Education Program. Handling Challenging Questions in the Management of CML.

• First Generation vs. Second Generation TKI – Which is Best At Diagnosis of Chronic Phase CML? Vivian G. Oehler, MD.
• When is it safe to stop TKIs? Delphine Rea, MD, Ph.D.
• How to manage CML patients with comorbidities? Jorge E. Cortes, MD.

632: Chronic Myeloid Leukemia: Therapy: CML: New and Beyond.

• 647 Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. Hagop M. Kantarjian, MD
• 648 Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS). Monica Bocchia
• 649 COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. Delphine Rea, MD, PhD
• 650 Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. Jorge E. Cortes, MD
• 651 Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials. Qian Jiang, MD
• 652 Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. Jorge E. Cortes, MD.

Special Interest Session: The 2020 Pandemic: Latest Insights on COVID-19.

• Do COVID-19 Patients Face Increased Risk of Thrombosis? Saskia Middeldorp, MD, PhD.
• How Can Community-Based Surveillance Strategies for Sars-Cov-2 Inform Pandemic Planning? Helen Chu, MD, MPH.

Education Program: Improving Symptom Control for Children with Hematological Malignancies.

Conversations on CML – CML Highlights from ASH 2020